セッション情報 The 2nd JSGE International Topic Conference Poster Session

Oxidative Stress and Apptosis

タイトル IT-P-24:

Changes of Cytokines in Cirrhosis Patients with Advanced Hepatocellular Carcinoma Treated by Sorafenib

演者 Nagai Hidenari(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, Japan)
共同演者 Kanekawa Takenori(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, Japan), Kobayashi Kojiro(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, Japan), Mukozu Takanori(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, Japan), Matsui Daigo(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, Japan), Matsui Teppei(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, Japan), Kanayama Masahiro(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, Japan), Momiyama Koichi(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, Japan), Ikehara Takashi(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, Japan), Ishii Koji(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, Japan), Igarashi Yoshinori(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, Japan), Sumino Yasukiyo(Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, Japan)
抄録 BACKGROUND:Tumor necrosis factor(TNF)is known to induce apoptosis of tumor cells by binding to TNF-related apoptosis-inducing ligand. Binding of the Fas ligand on cytotoxic T lymphocytes to the Fas receptor on hepatocytes also causes apoptosis. AIM:The aim of this study was to clarify changes of cytokines in LC patients with advanced HCC(aHCC)during sorafenib(SF)treatment. PATIENTS/METHODS:Sixty-one adult Japanese LC patients with aHCC received SF therapy between 2009 and 2012 at our hospital. SF was administered at 200-800 mg/day for 4 weeks. Serum levels of TNF-alpha, soluble TNF-receptor(sTNF-R), soluble Fas ligand(sFas L), and soluble Fas(sFas)were evaluated. RESULTS:Eight patients received SF at 200 mg/day(group 200), 45 patients were given 400 mg/day(group 400), and 8 patients were given 800 mg/day(group 800), while there were 4 dropouts. The serum level of TNF-alpha was significantly increased after treatment compared with before treatment in group 400 and group 800, although sTNF-R levels were significantly increased after treatment compared with before treatment in group 400. The serum level of sFas was significantly decreased after treatment compared with before treatment in groups 400 and 800, although the serum level of sFas L never exceeded 0.15 ng/ml. CONCLUSIONS:These results indicate that administration of SF at doses>400 mg/day might induce TNF-related or Fas-induced apoptosis by increasing serum levels of TNF-alpha or decreasing sFas.
索引用語